Mechanisms of histone deacetylase inhibitor in treating T-cell lymphoma and related clinical trials
10.3969/j.issn.1000-8179.20141434
- VernacularTitle:组蛋白去乙酰化酶抑制剂治疗T细胞淋巴瘤的作用机制及临床研究进展
- Author:
Huilai ZHANG
;
Huijuan LV
;
Huaqing WANG
- Publication Type:Journal Article
- Keywords:
HDACI;
mechanism;
clinical trials;
T-cell lymphoma
- From:
Chinese Journal of Clinical Oncology
2014;(19):1213-1216
- CountryChina
- Language:Chinese
-
Abstract:
Histone deacetylase inhibitors (HDACI) can improve the acetylation status of histone N-terminal, which will exert the effect on treatment. The N-terminal of histone modifications belongs to the category of epigenetics. Epigenetics mainly refers to the study of the heritable variation without change in DNA sequence. HDACI had been paid much attention as a new non-cytotoxic an-ti-cancer targeted drug. Thus, the application of this drug in clinical research is widespread. After the U.S. Food and Drug Administra-tion approved two HDACIs for the treatment of cutaneous T-cell lymphoma, the clinical applications of HDACI in other subtypes of T-cell lymphoma have obtained increasing attention. Studies on the mechanism of HDACI provide the theoretical basis for the applica-tion of HDACIs in other subtypes of T-cell lymphoma. In this article, we reviewed the mechanism and clinical trials of HDACIs on the treatment of T-cell lymphoma.
